The Technical Analyst
Ligand Pharmaceuticals [LGND]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ligand Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.24% $71.25
America/New_York / 26 apr 2024 @ 12:44
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 261.41 mill |
| EPS: | 3.03 |
| P/E: | 23.51 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 17.71 mill |
| Avg Daily Volume: | 0.175 mill |
| RATING 2024-04-26 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 23.51 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 4.00x |
| Company: PE 23.51 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$26.36 (-63.00%) $-44.88 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 68.57 - 74.08 ( +/- 3.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Davis Todd C | Buy | 3 556 | Common Stock |
| 2024-03-25 | Davis Todd C | Buy | 2 156 | Common Stock |
| 2024-03-25 | Davis Todd C | Buy | 2 855 | Common Stock |
| 2024-03-25 | Davis Todd C | Buy | 7 448 | Common Stock |
| 2024-03-25 | Davis Todd C | Sell | 2 156 | Non-Qualified Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 78.13 |
| Last 99 transactions |
| Buy: 889 086 | Sell: 99 886 |
Forecast:
14:23 - $71.53
Live Trading Signals (every 1 min)
Forecast
1: 12:53 - $71.21
Forecast 2: 13:43 - $72.11
Forecast 3: 14:23 - $71.53
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $71.25 (1.24% ) |
| Volume | 0.0199 mill |
| Avg. Vol. | 0.175 mill |
| % of Avg. Vol | 11.38 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LGND
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $75.38 | N/A | Active |
|---|
LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Latest Press Releases
2024-04-23 08:31:00 - Press Release
Ligand To Report First Quarter 2024 Financial Results On May 7, 2024
Jupiter, fla.--(business wire)--ligand pharmaceuticals incorporated (nasdaq: lgnd) today announced that it will report first quarter 2024 financial results after the close of the u.s. financial markets on tuesday, may 7, 2024, and will hold a conference call at 4:30 p.m. eastern time that same day to discuss financial results and provide a general business update. conference call and webcast information date: tuesday, may 7, 2024 time: 4:30 p.m. eastern time (1:30 p.m. pacific time) conference.
2024-04-08 08:15:00 - Press Release
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented At 9th London-innsbruck Colloquium On Status Epilepticus And Acute Seizures Conference
London--(business wire)--ligand pharmaceuticals incorporated (nasdaq: lgnd) today announced that its partners at the university of minnesota (umn) and curx pharmaceuticals, inc. presented new data on captisol-enabled™ topiramate injection (iv topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible. the poster was featured at the 9th london-innsbruck colloquium on status epilepticus a.
2024-04-03 09:00:00 - Press Release
Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of Zelsuvmi™
Jupiter, fla. & durham, n.c.--(business wire)--ligand pharmaceuticals (nasdaq: lgnd) today announced the launch of pelthos therapeutics (pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive scott plesha to the role of chief executive officer. pelthos is committed to commercializing innovative, safe, and efficacious therapeutic products to help patients impacted by diseases with limited treatment options. the company's lead product is zelsuvmi™ (berdazimer) t.
2024-03-05 16:01:00 - Press Release
Ligand Pharmaceuticals To Present At Barclays 26th Annual Global Healthcare Conference
San diego--(business wire)--ligand pharmaceuticals incorporated (nasdaq: lgnd) today announced that chief executive officer todd davis and chief financial officer tavo espinoza will participate in a fireside chat at the barclays 26th annual global healthcare conference in miami on thursday, march 14, 2024, at 10:45 a.m. eastern time. management will participate in one-on-one investor meetings during the conference. investors interested in meeting with ligand should contact their barclays repres.
2024-03-04 08:00:00 - Press Release
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San diego--(business wire)--ligand pharmaceuticals incorporated (nasdaq: lgnd) today announced that effective march 1, 2024, ligand's human capital management and compensation committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. the grant date for the options was march 1, 2024. the award was granted under ligand's 2022 employment inducement plan, as amended (the “inducement plan”) as an employment inducem.
Latest News
2024-04-23 08:31:00 - Business Wire
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Tuesday, May 7, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conference.
2024-04-17 10:55:33 - Zacks Investment Research
Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-04-08 14:46:24 - InvestorPlace
7 Small-Cap Stocks for the Thinking Speculator
It may sound counterintuitive but if you want big gains, you have to think small, as in small-cap stocks. Here, the idea is to trade predictability for maximum profit potential.
2024-04-05 19:06:07 - Zacks Investment Research
Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts
Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.
2024-04-04 10:36:11 - Zacks Investment Research
Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
2024-04-04 10:05:36 - Zacks Investment Research
Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know
Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2024-04-01 19:20:40 - Zacks Investment Research
Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $73.60, marking a +0.68% move from the previous day.
2024-03-26 19:21:16 - Zacks Investment Research
Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $68.64, indicating a -0.88% shift from the previous trading day.
2024-03-21 10:01:11 - Zacks Investment Research
Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock
Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
2024-03-20 19:06:19 - Zacks Investment Research
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $73.11, indicating a +1.25% shift from the previous trading day.